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Abstract 
Background: Infections can influence bone metabolism of neonates, which may lead to 
changes in some bone metabolism biomarkers. The purpose of this study was to determine 
whether  serum  bone  alkaline  phosphatase  (BALP),  osteocalcin  (OC)  and  beta  car-
boxy-terminal peptide of type I collagen (CTX), as specific biomarkers of bone metabolism, 
can be used to assess the severity of neonatal infections. 
Methods: Sixty-three neonates in the NICU were enrolled in this study. The neonates were 
divided into infected group (n=33) and non-infected group (n=30). The scores for neonatal 
acute physiology-perinatal extension II (SNAPPE-II) were calculated and interleukin-6 (IL-6), 
procalcitonin (PCT), BALP, OC and CTX were measured among the neonates with or 
without infections, and among the infected neonates before and after treatment.  
Results:  The  serum  BALP  levels  were  lower  in  the  infected  group  than  that  in  the 
non-infected group (p<0.01). The serum BALP levels increased markedly in the infected 
neonates after treatment (p<0.01). The serum BALP levels were also inversely correlated 
with SNAPPE-II of infected neonates before and after treatment (r=-0.56, p<0.05; r=-0.37, 
p<0.05, respectively). In infected neonates, the differences between serum BALP levels before 
and after treatment were inversely correlated with those of IL-6 levels (p<0.05). There were 
no significant changes in the OC, CTX and PCT levels in the infected or non-infected group 
before and after treatment. 
Conclusion: Our data suggest that serum BALP level might be used as a marker for assessing 
the severity of illness in infected neonates. 
Key words: Bone alkaline phosphatase, bone, severity, infection, neonates 
Introduction 
Infectious diseases frequently occur in the neo-
natal intensive care unit (NICU). Because of the close 
correlation  between  better  outcomes  and  prompt 
treatment, effective methods for assessment of illness 
severity should be established [1]. For this purpose, 
several  scoring  systems,  including  the  score  for  the 
neonatal  acute  physiology-perinatal  extension  II 
(SNAPPE-II),  has  been  developed  specifically  to 
quantify neonatal illness severity in the NICU popu-
lation [2]. As an empirically-validated illness severity 
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and mortality risk score, SNAPPE-II has been shown 
to have good calibration and discrimination values [2, 
3].  It  is  intuitive  clinically  that  the  higher  the 
SNAPPE-II, the sicker the neonate, but the data which 
are needed for the calculation of SNAPPE-II are dif-
ficult to be collected completely [4]. 
Some  laboratory  tests,  such  as  interleukin-6 
(IL-6) and procalcitonin (PCT), are also used to sup-
port the diagnosis and determine the severity of neo-
natal sepsis [5, 6]. IL-6 is an important cytokine of the 
early host response to infections. IL-6 increased rap-
idly  in  patients  exposed  to  bacterial  endotoxin  and 
falls precipitously following effective treatment, thus 
IL-6 is used as an early and sensitive marker of neo-
natal sepsis [5, 7]. PCT is mainly produced by mono-
cytes and hepatocytes, and the concentration of PCT 
began  to  rise  within  4  hours  after  the  patients’ 
expososure to bacterial endotoxin, and peaked at 6-8 
hours and decreased to normal levels after receiving 
effective treatment within 24 hours [8]. PCT was once 
considered as a more promising septic marker than 
other  markers,  while  recent  studies  have  provided 
conflicting results, especially in critical care settings 
[6, 8, 9].  
Bone is a complex organ with multiple functions 
[10], such as regulating hematogenesis [11], affecting 
immune  function  [12],  and  influencing  energy  me-
tabolism [13, 14]. Bone is mainly composed of osteo-
blasts  (OBs)  and  osteoclasts  (OCLs).  Bone  alkaline 
phosphatase (BALP), as the specific functional marker 
of  OBs,  is  released  into  the  circulation  after  being 
produced by OBs, and serum BALP levels can be used 
to evaluate the activity of OBs. Moreover, absence of 
significant circadian variations is a salient feature of 
BALP [15, 16]. Osteocalcin (OC) is another biomarker 
of bone, which is mainly synthesized by OBs. After 
being produced, the majority of OC is incorporated 
into  bone  matrix,  and  is  released  into  circulation 
during  bone  resorption  [17,  18].  Carboxy-terminal 
peptide of type I collagen (CTX) is the short fragment 
at  C-terminal  domain  of  typeⅠcollagen  molecule, 
which is cleaved by OCLs and released into the cir-
culation during bone resorption, thus it is considered 
to be a specific functional marker of OCLs [19]. Pre-
vious studies in mice revealed that some stress situa-
tions, such as bleeding and inflammation, could affect 
the activities of OBs and OCLs [20]. Several clinical 
studies also found that inflammation could influence 
the functions of OBs and OCLs in adults and children 
[21-23]. Therefore, we hypothesized that bone metab-
olism  biomarkers  can  reflect  the  illness  severity  of 
infected neonates. To test this hypothesis, we inves-
tigated the relationships between serum BALP, OC, 
CTX, IL-6, and PCT levels, and SNAPPE-II in infected 
neonates  and  in  non-infected  neonates,  and  in  the 
infected  neonates  before  and  after  receiving  treat-
ment.  
Materials and methods  
Study  design:  In  this  study,  we  assessed  the 
neonatal  illness  severity  by  measuring  SNAPPE-II, 
serum  levels  of  IL-6  and  PCT,  and  evaluated  the 
changes  in  bone  metabolism  by  measuring  serum 
concentrations of BALP, OC and CTX, respectively. In 
addition, serum levels of PTH, 25-(OH)VD, two key 
molecules  regulating  bone  metabolism,  were  also 
measured.  By  comparing  the  levels  of  BALP,  OC, 
CTX,  SNAPPE-II,  IL-6,  PTH,  25-(OH)VD  and  PCT 
among  the  neonates  in  the  infected  group  and 
non-infected group, we tried to explore the relation-
ships among these parameters in the neonates with or 
without  infection,  as  well  as  before  and  after  treat-
ment.  
Study population: In this study, we observed a 
total number of 685 neonates admitted to NICU of the 
Pediatric Department of the Daping Hospital between 
August 2009 and March 2010. Among these infants, 
we included 104 neonates in the study and informed 
consent was obtained from the parents. The study was 
approved by the Ethics Committee of the Third Mili-
tary Medical University. Sixty-three neonates enrolled 
in thie study were classified into the infected group (n 
= 33) and non-infected group (n = 30) according to the 
criteria below, the procedure is shown in Figure 1.  
Inclusion criteria: The inclusion criteria were as 
follows: (1) term infant; (2) between 3 and 28 days old; 
(3) confirmed sepsis, severe skin infection, or pneu-
monia; and (4) no suspected muscular, neurologic, or 
bone diseases. 
Exclusion criteria: The exclusion criteria were as 
follows: (1) family history of bone diseases; (2) severe 
pathologic jaundice; (3) received steroid therapy; and 
(4) maternal smoking. 
The infected group consisted of 33 neonates with 
sepsis, severe skin infections, and pneumonia. Sepsis 
was defined by a positive blood culture and at least 
one  clinical  sign  or  symptom  from  each  of  at  least 
three of the following six categories: (1) heart rate > 
180 beats per minute or < 80 beats per minute or arte-
rial blood pressure (BP) below 2SD of the mean BP; (2) 
metabolic acidosis with a pH < 7.25 or poor peripheral 
perfusion; (3) respiratory distress or respiratory rate > 
60 per minute or respiratory pause lasting  > 10 se-
conds;  (4)  abdominal  distension  and/or  feeding  in-
tolerance; (5) central temperature > 37.5℃ lasting at 
least 4 hours; and (6) lethargy or convulsions.  Int. J. Biol. Sci. 2012, 8 
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FIGURE 1. Screening and enrollment of study neonates  
 
A diagnosis of pneumonia should meet all of the 
following criteria [24]: (1) negative blood culture; (2) 
radiographic evidence of pneumonia; (3) respiratory 
signs or symptoms; and (4) white blood cell count > 
25.0×103/mm3 or  <  5.0×103/mm3 or  elevated  imma-
ture/ total neutrophils (I/T) ratio > 0.20. 
Skin  infections  consist  of  cellulitis  (n  =  1)  and 
pustulosis  (n  =  2),  which  were  mainly  defined  by 
symptoms including skin color, skin temperature and 
the features of rash or erythema. 
The non-infected group included neonates with 
asphyxia neonatorum (n = 18), glycopenia (n = 7), and 
physiologic jaundice (n = 5); they had no clinical and 
laboratory evidence of infection at the time of sam-
pling. 
Laboratory tests: The data of all neonates were 
collected for calculating SNAPPE-II, and blood sam-
ples (about 1 ml) were obtained within 24 hours after 
admission to the NICU. The whole blood count was 
performed  immediately  by  using  an  automated 
counter. Serum was isolated within 30 min and pre-
served at -100℃ before analysis. These measurements 
were  repeated  every  72  hours  or  when  the  clinical 
conditions took a bad or a favorable turn and after 
complete  recovery.  The  serum  concentrations  of 
BALP, CTX, OC, PTH, 25-(OH)VD, IL-6 and PCT were 
compared with those of the initial assay.  
BALP  was  measured  by  an  electrochemilumi-
nescence immunoassay (ECL) with a Unicel DXI-800 
analyzer (Beckman Coulter Inc., Fullerton, CA, USA) 
using  the  Access  Ostase  kit  (Beckman  Coulter  Inc., 
Chaska, USA); the detection range was 0.2-120 μg/L. 
CTX was also measured by ECL with an Elecsys 
2010 (Roche Diagnostics, Mannheim, Germany) using 
the Elecsys-CrossLaps/serum kit (Roche Diagnostics); 
the detection range was 0.01-6.0 μg/L. 
N-terminal  midfragment  of  OC  (N-MID)  was 
measured by an enzyme linked immunosorbent assay 
(ELISA) according to the manufacturer’s instructions 
(Immunodiagnostic Systems, Boldon, UK); the detec-
tion range was 0.5-100 μg/L [25]. 
PTH was measured by ECL with an Elecsys 2010 
(Roche Diagnostics, Mannheim, Germany) using the 
Elecsys-CrossLaps/serum kit (Roche Diagnostics); the 
detection range was 1-3500 ng/L. 
25-(OH)VD was measured by ELISA according 
to the manufacturer’s instructions (Immunodiagnostic Int. J. Biol. Sci. 2012, 8 
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Systems,  Boldon,  UK);  the  detection  range  was 
47.7-144 nmol/L [25]. 
IL-6 was measured by an ELISA kit according to 
the manufacturer’s instructions (Dakewe Biotic, Bei-
jing, China); the detection range was 6.25-200 μg/L 
[25]. 
PCT was determined by an ELISA kit according 
to  the  manufacturer’s  instructions  (R&D  Systems, 
Minneapolis,  MN,  USA);  the  detection  range  was 
0.3-10 μg/L. 
Statistical  analysis:  Statistical  analyses  were 
performed  with  SPSS  13.0,  a  two-sided  significance 
level of < 0.05 was considered statistically significant. 
Descriptive  statistics  were  presented  as  the  mean, 
median,  standard  deviation  (SD),  maximum,  and 
minimum.  
We used the t-test or Mann-Whitney U test for 
between-group comparisons according to normal or 
non-normal  distribution  of  data,  as  appropriate. 
Within the infected group, we compared the values 
with baseline by a Wilcoxon signed-rank test. Corre-
lations between quantitative data were analyzed by 
Spearman’s correlation test. 
Results 
In this study, a total of 63 term neonates were 
enrolled (33 and 30 neonates were classified into the 
infected and non-infected group, respectively). While 
recording the clinical alterations intensively, we col-
lected blood samples within 24 hours after admission 
to  the  NICU  and  repeated  the  sampling  every  72 
hours thereafter. A total of 161 blood samples were 
obtained;  the  clinical  characteristics  of  all  infected 
neonates in this study are summarized in Table 1. 
 
TABLE 1 Demographics and clinical characteristics of the 
study infants.  
  Infected group 
n =33 
Non-infected group 
n = 30 
Female / Male  15/18  16/14 
Gestational age 
(week) 
40.63±2.20  39.81±1.58 
Birth weight 
 (grams) 
3304.00±523.20  3220.10±500.79 
Age ( days)  17 (4-26)  16 (3-27) 
Fever  7 (21.21%)  1 (3.33%)§ 
Hypoxia  19 (57.58%)  0 (0%)§ 
Apnea  4 (12.12%)  2 (6.67%)† 
Feeding intolerance  27 (81.81%)  4 (13.33%)§ 
†: represents p < 0.05 compared with infected group. 
§: represents p < 0.01 compared with infected group. 
 
 
In this study, the length of hospitalization of the 
infected and non-infected group was 9.27 ± 1.86 and 
7.70 ± 2.17 days, respectively. There were no signifi-
cant differences between the two groups with respect 
to the genders, gestational age, and body weight at 
birth.  We  found  a  significantly  higher  incidence  of 
hypoxia,  apnea,  and  feeding  intolerance  in  the  in-
fected group than in the non-infected group, as shown 
in Table 1, and the data of neonates with infection are 
shown in Table 2, although the mean leukocyte counts 
in  the  infected  group  were  higher  than  that  in  the 
non-infected group (13.31 ± 5.16 vs. 12.97 ± 4.79 ×109 
/L; p > 0.05).  
We  compared  PTH,  25-(OH)VD,  BALP,  OC, 
CTX,  SNAPPE-II,  PCT,  and  IL-6  levels  between  the 
infected  and  non-infected  groups  before  effective 
treatment.  We  found  that  BALP  was  significantly 
lower in the infected group than in the non-infected 
group (50.02 ± 15.39 vs. 64.07 ± 17.44 μg/L, p < 0.001). 
We also showed that the SNAPPE-II and IL-6 levels 
were higher in the infected group (23.6 ± 21.4 vs. 19.9 
± 14.3, p < 0.01; 37.45 ± 17.84 vs. 25.55 ± 8.77 ng/L, p < 
0.001, respectively). There were no significant differ-
ence in the PTH, 25-(OH)VD, CTX, OC and PCT levels 
between the two groups before treatment (30.87±13.03 
vs.  31.23±12.75  ng/L,  p  >  0.05;  181.86±53.38  vs. 
186.49±57.65 nmol/L, p > 0.05; 1.38 ± 0.39 vs. 1.35 ± 
0.33 μg/L, p > 0.05; 23.10±5.53 vs. 23.49±6.69 μg/L, p > 
0.05; 3.54 ± 1.23 vs. 4.28 ± 1.29 mg/L, P > 0.05, respec-
tively), as shown in Table 3. 
We  also  compared  these  markers  among  the 
neonates  before  and  after  receiving  effective  treat-
ments, and found a noticeable increase in the BALP 
concentration in the infected neonates after treatment 
(63.58 ± 19.63 vs. 50.02 ± 15.39 μg/L, p<0.001). A sig-
nificant decrease  in SNAPPE-II and IL-6 levels was 
also observed (13.7 ±15.9 vs. 23.6 ± 21.4, p < 0.01; 25.93 
± 7.98 vs. 37.45 ± 17.84μg/L, p < 0.001, respectively). 
There  was  a  significant  inverse  correlation  between 
BALP and SNAPPE-Ⅱ before and after treatment (r = 
-0.56, p= 0.025; r = -0.37, p = 0.04, respectively). The 
changes in BALP and IL-6 levels among the infected 
neonates  before  and  after  effective  treatments  are 
presented in Figure 2. Furthermore, the value differ-
ence between BALP levels before and after effective 
treatments was noted to be inversely correlated with 
the  value  difference  of  IL-6  (r  =  -0.65,  p<  0.01),  as 
shown  in  Figure  3.  We  also  measured  PTH, 
25-(OH)VD, OC, CTX and PCT in infected group be-
fore and after treatment, but no significant differences 
were revealed (Table 3). 
We also compared PTH, 25-(OH)VD, BALP, IL-6, 
CTX, OC, PCT and SNAPPE-Ⅱ among the neonates 
without infections before and after receiving effective Int. J. Biol. Sci. 2012, 8 
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treatment, but no significant changes were observed  (Table 3).  
TABLE 2 Data of infected neonates, including the measurements at the time of first blood sampling. 
Patient  Gender  Age 
(days) 
Type of 
infection 
WBC 
(×109/L) 
pH  PaO2 
(mmHg) 
FiO2 
(%) 
PaCO2 
(mmHg) 
BE 
(mmol/L) 
Temp 
(℃) 
BP 
(mmHg) 
1  M  3  Cellulitis  32.12  7.30  92  40  42.6  -6  36.6  65/43 
2  M  13  Sepsis●  10.74  7.43  81  40  38.3  1  36.8  77/45 
3  F  13  Pneumonia  21.41  7.31  52  21  45.4  1  37.4  84/44 
4  M  15  Pneumonia  7.28  7.45  88  21  36.7  2  37  90/60 
5  F  9  Pneumonia  10.76  7.35  43  35  53.4  4  36.5  94/58 
6  F  13  Pneumonia  9.51  7.47  107  21  30.4  -2  37  79/36 
7  F  14  Sepsis●  14.7  7.45  74  35  20.7  -3  37  71/47 
8  F  18  Pneumonia  11.19  7.37  61  21  38.8  -3  36.3  71/40 
9  M  23  Pneumonia  9.58  7.34  40  35  54.6  4  36.8  93/64 
10  F  11  Pneumonia  12.0  7.35  58  21  48.9  1  37.1  81/46 
11  M  19  Pneumonia  16.26  7.46  94  21  30.5  -2  37  80/39 
12  M  13  Pneumonia  12.03  7.39  85  21  35.9  -1  36.9  82/56 
13  M  13  Sepsis
◆  15.21  7.47  80  21  24.5  -6  36.5  70/44 
14  F  5  Sepsis※  11.0  7.45  46  21  31.4  -2  36.6  81/53 
15  F  15  Pneumonia  13.13  7.37  44  21  46.4  2  36.4  82/53 
16  M  27  Pneumonia  9.21  7.29  54  21  31.8  -11  37  75/42 
17  M  16  Pneumonia  15.2  7.4  59  21  42.7  2  36.2  83/49 
18  M  20  Pneumonia  8.43  7.51  118  21  28.6  0  36.6  72/53 
19  F  20  Pneumonia 
Sepsis● 
20.0  7.36  44  40  48.9  3  36.4  74/50 
20  M  10  Pneumonia  9.05  7.43  85  21  38.5  1  36.5  94/73 
21  F  13  Sepsis※  13.04  7.47  77  21  31.0  -1  36.4  82/53 
22  F  19  Pneumonia  7.8  7.37  54  21  42.4  -1  36.6  80/59 
23  M  20  Pneumonia  9.0  7.39  53  21  43.5  1  36.6  84/37 
24  M  14  Pneumonia  9.4  7.48  69  21  32.7  1  36.5  92/50 
25  F  11  Pneumonia  15.82  7.44  58  21  29.2  2  36.5  88/56 
26  M  15  Pustulosis  14.29  7.53  80  21  26.3  -1  37  90/60 
27  F  18  Pneumonia  21.08  7.41  62  21  38.2  0  36.8  88/54 
28  M  9  Pneumonia  10.0  7.45  67  35  41.9  -1  36.6  62/47 
29  M  15  Pneumonia  13.05  7.41  54  21  42,9  -2  37  80/58 
30  M  9  Sepsis※  20.96  7.57  140  21  23.3  0  36.4  72/41 
31  F  8  Pneumonia  15.12  7.45  84  21  29.2  -4  36  90/53 
32  M  22  Sepsis●  10.18  7.37  68  21  44.7  0  36  102/58 
33  F  15  Pustulosis  10.8  7.36  49  21  42.9  -1  36.5  87/50 
Isolated bacteria from blood. ●: Staphylococcus epidermidis ※: Klebsiella pneumoniae ◆: Pseudomonas aeruginosa 
 
TABLE 3 Comparison of PCT, IL-6, PTH, 25-(OH)VD, OC, BALP, CTX and SNAPPE-II between non-infected group and 
infected group before and after effective treatments. 
  Non-infected group    Infected group 
Before treatment 
n = 30 
After 
treatment 
n =30 
  Before  
treatment 
n = 31 
After  
treatment 
n =31 
PCT (mg/L) 
Median 
 
3.69 
 
3.53 
   
4.19 
 
3.88 
Mean±SD 
95%CI 
3.54±1.23 
2.95-4.46 
3.30±0.99 
2.58-4.44 
 
 
4.28±1.29 
3.83-4.74 
3.97±1.56 
3.43-4.51 
IL-6 (ng/L) 
Median 
 
26.42 
 
25.73 
   
30.96 
 
24.54 
Mean±SD 
95%CI 
25.55±8.77a 
21.42-30.10 
25.91±9.10 
22.59-29.31 
 
 
37.45±17.84§§ 
30.90-43.99 
25.93±7.98b 
22.00-28.85 Int. J. Biol. Sci. 2012, 8 
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  Non-infected group    Infected group 
Before treatment 
n = 30 
After 
treatment 
n =30 
  Before  
treatment 
n = 31 
After  
treatment 
n =31 
PTH (ng/L)           
 Median  28.60  27.94    30.29  31.11 
Mean±SD  30.87±13.03  29.98±14.26    31.23±12.75  32.29±10.76 
95%CI  26.59-39.77  25.04-41.00    26.79-40.99  25.54-39.86 
25-(OH)VD (nmol/L)           
Median  187.5  181.88    183.2  178.9 
Mean±SD  181.86±53.38  179.90±46.09    186.49±57.65  188.34±50.10 
95%CI  163.68-209.29  137.25-226.5    167.20-211.32  154.09-220.77 
OC (μg/L)           
Median  22.99  23.13   
 
23.79  23.35 
Mean±SD  23.10±5.53  22.95±4.36    23.49±6.69  23.12±5.17 
95%CI   20.33-27.42  19.83-26.25    20.85-26.14  18.80-27.44 
BALP (μg/L) 
Median 
 
63.10 
 
62.47 
 
 
 
50.76 
 
61.58 
Mean±SD 
95%CI 
64.07±17.4a 
53.24- 72.03 
62.01±16.52 
49.15-69.98 
 
 
50.02±15.39§§ 
44.28-55.77 
63.58±19.63b 
56.25-70.90 
CTX (μg/L)           
Median  1.40  1.33    1.29  1.34 
Mean±SD  1.38±0.39  1.42±0.22    1.35±0.33  1.37±0.26 
95%CI  1.17-1.54  1.23-1.48    1.20-1.50  1.26-1.49 
SNAPPE-Ⅱ           
Range  0-32  0-24    0-58  0-65 
Median  21a  14    33 §  16b 
Mean±SD  19.9±14.3  12.1±11.1    23.6±21.4  13.7±15.9 
§: compared with a and b, p<0.01; §§: compared with a and b, p<0.001. 
 
 
 
 
FIGURE 2. The difference values of BALP and IL-6 in infected neonates before and after treatment. Black points represent 
BALP and stars represent IL-6. BALP: bone alkaline phosphatase; IL-6: interleukin-6. Int. J. Biol. Sci. 2012, 8 
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FIGURE 3. The correlation between the difference value of BALP and that of IL-6 before and after treatment. IL-6: in-
terleukin-6; BALP: bone alkaline phosphatase. 
 
Discussion 
The aim of this work was to study whether the 
serum levels of bone metabolism biomarkers can be 
used to assess the severity of infected neonates. The 
main finding was that serum BALP, as a marker of 
bone formation, may be used as a marker to assess 
illness severity of infected neonates. 
As a specific marker of bone formation, the se-
rum BALP level is affected by the number and activity 
of  OBs.  We  found  a  depressed  activity  and  an  in-
creased apoptotic number of OBs in septic mice (un-
published data), and another experiment in mice also 
exhibited  a  similar  result  [20].  In  this  study,  as  ex-
pected,  we  found  that  serum  BALP  concentrations 
were  lower  in  infected  neonates  than  those  in 
non-infected neonates.  
PTH and Vitamin D play essential role in regu-
lating bone metabolism [26, 27], we measured serum 
levels of PTH and 25-(OH)VD, and found no signifi-
cant changes between the neonates with and without 
infections, and the infected neonates before and after 
treatment. Our data indicated that, in this study, the 
changes of serum BALP concentrations were not re-
lated to PTH and Vitamin D activity. 
We also measured the serum levels of another 
bone marker, OC, in those neonates. It is known that 
OC is deposited in bone matrix after being produced 
by OBs, and is released into circulation during bone 
resorption.  Thus,  OC  is,  in  fact,  a  marker  for  bone 
turnover, and changes in the activity of both OBs and 
OCLs can affect the blood concentrations of OC [18]. 
Previous  study  demonstrates  that  N-MID  of  OC  is 
more  reliable  than  intact  OC  for  evaluating  bone 
turnover state [28]. In this study, we measured N-MID 
of OC and found no significant changes in it between 
infected group and non-infected group. Similarly, an 
earlier  study  also  showed  unchanged  levels  of  OC 
between the neonates with and without infection [23]. 
Whether  this  result  indicates  that  makers  for  bone 
formation are more sensitive than those bone turno-
ver  makers  in  assessing  illness  severity  is  currently 
unknown.  
Because SNAPPE-Ⅱ is clinically used to evaluate 
the physiologic changes and assess the illness severity 
of  neonates  [29],  we  explored  the  relationship  be-
tween BALP and SNAPPE-Ⅱ in this study. Our re-
sults showed that SNAPPE-Ⅱ was higher in the in-
fected  group  than  it  in  the  non-infected  group. 
Among the infected neonates, SNAPPE-II was higher 
before receiving treatments than that after receiving 
treatments,  the  findings  were  similar  to  a  previous 
study which reported that SNAPPE-II was an empir-
ically-validated parameter for assessing illness sever-
ity [2]. We found inverse correlations between BALP 
and SNAPPE-Ⅱ in infected neonates before or after 
effective treatment, which further suggests that BALP Int. J. Biol. Sci. 2012, 8 
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may be used to assess illness severity of neonates with 
infection. 
IL-6  is  considered  to  be a  valuable  marker  for 
assessing illness severity of patients with sepsis [30, 
31]. In this study, we also analyzed the relationship 
between  the  BALP  and  IL-6  levels  in  infected  and 
non-infected  neonates,  and  in  the  infected  neonates 
before and after receiving effective treatment. In in-
fected neonates, we observed that the value difference 
in BALP level before and after the effective treatments 
was inversely correlated with that of IL-6, while no 
significant  relationship  between  the  BALP  and  IL-6 
levels was found. Because IL-6 levels are correlated 
with clinical severity, the finding of the relationship 
between BALP and IL-6 levels further supports that 
BALP levels may reflect illness severity of the infected 
neonates. As the levels of serum BALP are dynami-
cally changed in patients, a dynamic observation of 
BALP should be more accurate for assessing the se-
verity of illness. 
Previous  studies  have  shown  increased  OCLs 
activity  in  septic  mice  and  premature  infants  with 
necrotizing enterocolitis [10, 23, 32, 33], but Cakir et al. 
[24] found no significant difference in CTX between 
the neonates with some kinds of bacterial sepsis and 
with some diseases such as respiratory distress syn-
drome,  congenital  heart  disease,  pneumothorax  or 
neonatal pneumonia. In this study, we also found no 
significant changes in CTX levels between the infected 
and non-infected groups. Because the levels of CTX 
can  be  affected  by  both  inflammatory  factors 
or non-inflammatory  factors,  we  speculate  that  this 
may be the reason for the absence of changes in CTX 
level in our study. Additionally, infections caused by 
different  pathogens  may  be  another  reason  for  the 
insignificant change of CTX. Based on our previous 
works, we also speculate that the increased apoptosis 
of  OCLs  in  sepsis  should  not  be  ruled  out  (un-
published data). 
PCT is a promising diagnostic marker used re-
cently to help the diagnosis of sepsis and is also an 
indicator  of  the  severity  of  sepsis  [34,  35],  but 
false-negative cases have been found. A study showed 
that  PCT  is  not  sufficiently  reliable  to  be  the  sole 
marker  of  sepsis  [6].  Other  studies  indicated  that 
non-specific inflammation,  such  as  respiratory  dis-
tress syndrome and acute lung or inhalation injuries 
can also result in an increased serum PCT concentra-
tion  in  newborn  infants  [36,  37].  In  this  study,  we 
found no significant changes in PCT between the in-
fected and non-infected group, as well as infants be-
fore and after treatment. The synergic effects of infec-
tion and non-specific inflammation on the PCT syn-
thesis may be one of the reasons for this result. An-
other likely explanation is that the inflammations of 
the  infected  neonates  might  be  caused  by  different 
pathogens,  this  heterogeneity  may  cause  various 
changes in PCT levels.  
Our study has some limitations. Because it’s very 
difficult  to  obtain  blood  samples 
from healthy neonates  for  study  purpose,  we  didn’t 
have  chance  to  compare  the  changes  in  bone  bi-
omarkers  and  inflammatory  factors  be-
tween healthy and infected neonates.  Given  the  fact 
that  the  link  between  serum  BALP  and  infection  is 
established, it is possible that the association may also 
be caused by the random observation. Although this 
study  suggests  the  role  of  bone  biomarkers  in  as-
sessing ill severity of infected neonates, further stud-
ies  are  needed  to  evaluate  whether  combination  of 
serum BALP and other biomarkers such as IL-6 can 
improve the accuracy in assessing illness severity of 
neonatal infection.  
In summary, the BALP level, with its lack of sig-
nificant  circadian  variation  and  convenience  of 
measurement  by  an  electrochemiluminescence  im-
munoassay, can be potentially used to assess the ill-
ness severity of infected neonates. As far as we know 
this is the first report about the assessment of illness 
severity using bone metabolic biomarkers, and further 
studies  are  needed  to  confirm  our  results  in  larger 
groups of patients. 
Acknowledgements  
We thank Fengtao Luo for his help in statistical 
analysis.  This  study  was  supported  by  the  Special 
Funds  for  Major  State  Basic  Research  Program  of 
China (973 Program, No. 2011CBP64701), Program for 
Changjiang  Scholars  and  Innovative  Team  (No. 
IRT0712); Natural Science Foundation of China (No. 
81030036, and No. 30530410). 
Conflict of Interests 
The authors have declared that no conflict of in-
terest exists. 
References 
1   Chiesa C, Pacifico L, Rossi N, Panero A, Matrunola M, Mancuso 
G.  Procalcitonin as a marker of nosocomial  infections  in  the 
neonatal intensive care unit. Intensive care medicine. 2000; 26 
Suppl 2: S175-177. 
2  Richardson DK, Corcoran JD, Escobar GJ, Lee SK. SNAP-II and 
SNAPPE-II: Simplified newborn illness severity and mortality 
risk scores. The Journal of pediatrics. 2001; 138: 92-100. 
3  Hoehn  T,  Drabik  A, Lehmann C,  Christaras  A,  Stannigel  H, 
Mayatepek  E.  Correlation  between  severity  of  disease  and 
reimbursement  of  costs  in  neonatal  and  paediatric  intensive 
care patients. Acta Paediatr. 2008; 97: 1438-1442. Int. J. Biol. Sci. 2012, 8 
 
http://www.biolsci.org 
38 
4  Dorling  JS,  Field  DJ.  Value  and  validity  of  neonatal  disease 
severity  scoring  systems.  Archives  of  disease  in  childhood. 
2008; 93: F80-82. 
5  Kocabas E, Sarikcioglu A, Aksaray N, Seydaoglu G, Seyhun Y, 
Yaman  A.  Role  of  procalcitonin,  C-reactive  protein, 
interleukin-6, interleukin-8 and tumor necrosis factor-alpha in 
the  diagnosis  of  neonatal  sepsis.  The  Turkish  journal  of 
pediatrics. 2007; 49: 7-20. 
6  Lopez Sastre JB, Perez Solis D, Roques Serradilla V, Fernandez 
Colomer B, Coto Cotallo GD, Krauel Vidal X, et al. Procalcitonin 
is  not  sufficiently  reliable  to  be  the  sole  marker  of  neonatal 
sepsis of nosocomial origin. BMC Pediatr. 2006; 6: 16. 
7  Kuster  H,  Weiss  M,  Willeitner  AE,  Detlefsen  S,  Jeremias  I, 
Zbojan  J,  et  al.  Interleukin-1  receptor  antagonist  and 
interleukin-6  for  early  diagnosis  of  neonatal  sepsis  2  days 
before clinical manifestation. Lancet. 1998; 352: 1271-1277. 
8  van  Rossum  AM,  Wulkan  RW,  Oudesluys-Murphy  AM. 
Procalcitonin as an early marker of infection in neonates and 
children. The Lancet infectious diseases. 2004; 4: 620-630. 
9  Santuz P, Soffiati M, Dorizzi RM, Benedetti M, Zaglia F, Biban 
P. Procalcitonin for the diagnosis of early-onset neonatal sepsis: 
a multilevel probabilistic approach. Clinical biochemistry. 2008; 
41: 1150-1155. 
10  Lorenzo J, Horowitz M, Choi Y. Osteoimmunology: interactions 
of the bone and immune system. Endocr Rev. 2008; 29: 403-440. 
11  Adams GB, Martin RP, Alley IR, Chabner KT, Cohen KS, Calvi 
LM,  et  al.  Therapeutic  targeting  of  a  stem  cell  niche.  Nat 
Biotechnol. 2007; 25: 238-243. 
12  Lee  SH,  Kim  TS,  Choi  Y,  Lorenzo  J.  Osteoimmunology: 
cytokines and the skeletal system. BMB Rep. 2008; 41: 495-510. 
13  Lee NK, Sowa H, Hinoi E, Ferron M, Ahn JD, Confavreux C, et 
al. Endocrine regulation of energy metabolism by the skeleton. 
Cell. 2007; 130: 456-469. 
14  Ferron M, Wei J, Yoshizawa T, Del Fattore A, Depinho RA, Teti 
A,  et  al.  Insulin  Signaling  in  Osteoblasts  Integrates  Bone 
Remodeling and Energy Metabolism. Cell. 2010; 142: 296-308. 
15  Seibel MJ. Molecular markers of bone turnover: biochemical, 
technical and analytical aspects. Osteoporos Int. 2000; 11 Suppl 
6: S18-29. 
16  Uemura  H,  Yasui  T,  Kiyokawa  M,  Kuwahara  A,  Ikawa  H, 
Matsuzaki T, et al. Serum osteoprotegerin/osteoclastogenesis- 
inhibitory  factor  during  pregnancy  and  lactation  and  the 
relationship  with  calcium-regulating  hormones  and  bone 
turnover  markers.  The  Journal  of  endocrinology.  2002;  174: 
353-359. 
17  Hauschka  PV,  Lian  JB,  Cole DE,  Gundberg CM. Osteocalcin 
and matrix Gla protein: vitamin K-dependent proteins in bone. 
Physiol Rev. 1989; 69: 990-1047. 
18  Lee AJ, Hodges S, Eastell R. Measurement of osteocalcin. Ann 
Clin Biochem. 2000; 37 ( Pt 4): 432-446. 
19  Garnero P. Biomarkers for osteoporosis management: utility in 
diagnosis, fracture risk prediction and therapy monitoring. Mol 
Diagn Ther. 2008; 12: 157-170. 
20  Katayama  Y,  Battista  M,  Kao  WM,  Hidalgo  A,  Peired  AJ, 
Thomas SA, et al. Signals from the sympathetic nervous system 
regulate  hematopoietic  stem  cell  egress  from  bone  marrow. 
Cell. 2006; 124: 407-421. 
21  Moyer-Mileur LJ, Brunstetter V, McNaught TP, Gill G, Chan 
GM.  Daily  physical  activity  program  increases  bone 
mineralization and growth in preterm very low birth weight 
infants. Pediatrics. 2000; 106: 1088-1092. 
22  Vestergaard  P.  Bone  loss  associated  with  gastrointestinal 
disease:  prevalence  and  pathogenesis.  Eur  J  Gastroenterol 
Hepatol. 2003; 15: 851-856. 
23  Cakir M, Mungan I, Karahan C, Can G, Okten A. Necrotizing 
enterocolitis increases the bone resorption in premature infants. 
Early human development. 2006; 82: 405-409. 
24  Dollner H, Vatten L, Austgulen R. Early diagnostic markers for 
neonatal  sepsis:  comparing  C-reactive  protein,  interleukin-6, 
soluble tumour necrosis factor receptors and soluble adhesion 
molecules. Journal of clinical epidemiology. 2001; 54: 1251-1257. 
25  Chiesa  C,  Pellegrini  G,  Panero  A,  Osborn  JF,  Signore  F, 
Assumma  M,  et  al.  C-reactive  protein,  interleukin-6,  and 
procalcitonin in the immediate postnatal period: influence of 
illness  severity,  risk  status,  antenatal  and  perinatal 
complications, and infection. Clinical chemistry. 2003; 49: 60-68. 
26  Somjen D, Tordjman K, Katzburg S, Knoll E, Sharon O, Limor 
R,  et  al.  Lipoxygenase  metabolites  are  mediators  of 
PTH-dependent  human  osteoblast  growth.  Bone.  2008;  42: 
491-497. 
27  Kulkarni NH, Wei T, Kumar A, Dow ER, Stewart TR, Shou J, et 
al. Changes in osteoblast, chondrocyte, and adipocyte lineages 
mediate the bone anabolic actions of PTH and small molecule 
GSK-3 inhibitor. J Cell Biochem. 2007; 102: 1504-1518. 
28  Nagasue K, Inaba M, Okuno S, Kitatani K, Imanishi Y, Ishimura 
E, et al. Serum N-terminal midfragment vs. intact osteocalcin 
immunoradiometric assay as markers for bone turnover and 
bone  loss  in  hemodialysis  patients.  Biomed  Pharmacother. 
2003; 57: 98-104. 
29  Dorling JS, Field DJ, Manktelow B. Neonatal disease severity 
scoring  systems.  Archives  of  disease  in  childhood.  2005;  90: 
F11-16. 
30  Pettila V, Hynninen M, Takkunen O, Kuusela P, Valtonen M. 
Predictive value of procalcitonin and interleukin 6 in critically 
ill patients with suspected sepsis. Intensive care medicine. 2002; 
28: 1220-1225. 
31  Pathan  N,  Hemingway  CA,  Alizadeh  AA,  Stephens  AC, 
Boldrick JC, Oragui EE, et al. Role of interleukin 6 in myocardial 
dysfunction of meningococcal septic shock. Lancet. 2004; 363: 
203-209. 
32  Kollet O, Dar A, Shivtiel S, Kalinkovich A, Lapid K, Sztainberg 
Y,  et  al.  Osteoclasts  degrade  endosteal  components  and 
promote  mobilization  of  hematopoietic  progenitor  cells.  Nat 
Med. 2006; 12: 657-664. 
33  Walsh MC, Kim N, Kadono Y, Rho J, Lee SY, Lorenzo J, et al. 
Osteoimmunology: interplay between the immune system and 
bone metabolism. Annu Rev Immunol. 2006; 24: 33-63. 
34  Ng PC. Diagnostic markers of infection in neonates. Archives of 
disease in childhood. 2004; 89: F229-235. 
35  Tsalik  EL,  Woods  CW.  Sepsis  redefined:  the  search  for 
surrogate  markers.  International  journal  of  antimicrobial 
agents. 2009; 34 Suppl 4: S16-20. 
36  Lapillonne A, Basson E, Monneret G, Bienvenu J, Salle BL. Lack 
of specificity of procalcitonin for sepsis diagnosis in premature 
infants. Lancet. 1998; 351: 1211-1212. 
37  Monneret  G,  Labaune  JM,  Isaac  C,  Bienvenu  F,  Putet  G, 
Bienvenu  J.  Increased  serum  procalcitonin  levels  are  not 
specific  to  sepsis  in  neonates.  Clin  Infect  Dis.  1998;  27: 
1559-1561.  